Ari Ericson

Title: Ari Ericson: Innovator in Macrocyclic Inhibitors

Introduction

Ari Ericson is a notable inventor based in Thousand Oaks, CA (US). She has made significant contributions to the field of medicinal chemistry, particularly in the development of Mcl-1 inhibitors. Her innovative work has led to the creation of processes that enhance the synthesis of these important compounds.

Latest Patents

Ari holds a patent for the "Ring closing synthesis of macrocyclic MCL-1 inhibitor intermediates." This patent outlines processes for synthesizing Mcl-1 inhibitors and intermediates, including compound F, which can be utilized in their preparation. The patent specifically details the synthesis of compound A1 and compound A2, along with their respective salts and solvates.

Career Highlights

Ari is currently employed at Amgen Inc., a leading biotechnology company. Her work at Amgen has allowed her to focus on groundbreaking research and development in the pharmaceutical industry. With her expertise, she has contributed to advancements that may lead to new therapeutic options for patients.

Collaborations

Ari collaborates with talented colleagues, including Austin G Smith and Jason S Tedrow. These partnerships foster a creative environment that encourages innovation and the sharing of ideas.

Conclusion

Ari Ericson's contributions to the field of medicinal chemistry, particularly in the synthesis of Mcl-1 inhibitors, highlight her role as a key innovator. Her work at Amgen and her collaborations with fellow researchers underscore the importance of teamwork in driving scientific advancements.